2 completed, 2 recruiting, 2 terminated, 1 withdrawn. 5 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 2, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Hormone Receptor Positive Breast Adenocarcinoma: new trials by email Literature Review of Hormone Receptor Positive Breast Adenocarcinoma trials Research Report on Hormone Receptor Positive Breast Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors [225Ac]Ac-AKY-1189 (therapeutic), [64Cu]Cu-AKY-1189 (imaging) - Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC) | Phase 1 | Recruiting | Aktis Oncology, Inc. | 150 | 2025-08-22 | 2026-09-17 |
| Study of 68Ga-R10602 68Ga-R10602 injection - Locoregionally Recurrent Hormone-receptor Positive Breast Cancer, Metastatic Hormone Receptor Positive Breast Cancer | Phase 1 | Completed | Radionetics Oncology | 27 | 2024-12-10 | 2026-07-06 |
| Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study Palbociclib, Ribociclib, Abemaciclib - Breast Adenocarcinoma, Breast Cancer Stage IV | Recruiting | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 3500 | 2023-05-01 | 2025-02-03 | |
| Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer Abemaciclib, Niraparib Tosylate Monohydrate - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Phase 1 | Completed | OHSU Knight Cancer Institute | 8 | 2021-06-07 | 2026-01-29 |
| Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial Bintrafusp Alfa, Immunocytokine NHS-IL12, Radiation Therapy - Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Adenocarcinoma | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2021-03-07 | 2023-12-27 | |
| Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases Bintrafusp Alfa, Pimasertib, Quality-of-Life Assessment - Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 8 | 2021-01-15 | 2026-03-18 |
| Impact of Breast Cancer Treatment on Joint Health, Cartilage Composition, and Bone Structure in the Knee and Hand Magnetic Resonance Imaging, Questionnaire Administration - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Terminated | University of California, San Francisco | 8 | 2020-05-18 | 2022-09-09 |
Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Neoplasm Metastasis (2) · Triple Negative Breast Neoplasms (2) · Brain Neoplasms (1) · Breast Diseases (1) · Breast Neoplasms, Male (1) · Head and Neck Neoplasms (1) · Hematologic Neoplasms (1) · Lung Neoplasms (1) · Melanoma (1) · Unilateral Breast Neoplasms (1)
Neoplasms (5) · Neoplasms by Site (5) · Skin Diseases (5) · Skin and Connective Tissue Diseases (5) · Breast Diseases (4) · Breast Neoplasms (3) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Lung Diseases (2) · Neoplastic Processes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2)
abemaciclib (2) · bintrafusp alfa protein, human (2) · Magnetic Resonance Spectroscopy (1) · N-(2,3-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamide (1) · NHS-IL12 immunocytokine (1) · Radiation (1) · Radiotherapy (1) · Therapeutics (1) · X-Rays (1) · niraparib (1) · palbociclib (1) · ribociclib (1)
M.D. Anderson Cancer Center (2) · Aktis Oncology, Inc. (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · OHSU Knight Cancer Institute (1) · Radionetics Oncology (1) · University of California, San Francisco (1)
United States (5) · Italy (1)
Alexandra Zimmer, M.D. (1) · Hussein A Tawbi, MD (1) · Meghan Karuturi, MD (1) · Roland Krug, PhD (1)